Comparative effectiveness research is going to have a huge impact on every stakeholder in healthcare delivery. It requires a much broader view of the healthcare system so that information will exist about a patient’s outcome as he or she moves from diagnosis to treatment in the healthcare system.
Comparative effectiveness data are geared broadly to multiple decision makers to provide real-world evidence of the outcomes of various treatments. But challenges remain about developing high-quality data and how those data will be used.
For physicians, comparative effectiveness is going to provide the ability to analyze treatment choices and pick what’s best for their individual patients. For patients, it’s going to provide them with a lot more information that can help set their expectations for their treatment. For payers, comparative effectiveness will provide support for decision-making…
Good CER Practices
The Real World of Comparative Effectiveness Research
Comparative Research Priorities
Consumers Are Skeptical About Evidence-Based Healthcare
Health Economics Spending Increases 45% in Emerging Markets; 8% in the U.S.
Larry Atkins. Executive Director, U.S. Public Policy, Merck & Co. Inc., a global healthcare leader that provides prescription medicines, vaccines, biologic therapies, and consumer care and animal health products. For more information, visit merck.com.
Lee Blansett. Senior VP, Kantar Health, a healthcare-focused global consultancy and marketing insights company. For more
information, visit kantarhealth.com.
J. Jaime Caro. Senior VP of Health Economics, United BioSource Corp., a global scientific and medical affairs organization that partners with life-sciences companies. For more information, visit unitedbiosource.com.
Nick Colucci. President and CEO, Publicis Healthcare Communications Group, a network of healthcare communications agencies. For more information, visit publicishealthcare.com.
Bill Crown, Ph.D. President, i3 Innovus, provides a scientific view of the marketplace — health economics, outcomes, and late-phase research — to deliver the scientific evidence at any phase of the product lifecycle. For more information, visit i3global.com.
John Doyle, Dr. P.H. VP and Practice Leader for the Consulting Group, Quintiles, a fully integrated biopharmaceutical services company offering clinical, commercial, consulting, and capital solutions worldwide. For more information, visit quintiles.com/consulting.
Richard Gliklich, M.D. President and CEO, Outcome, a leading provider of patient registries, studies, quality improvement programs, and integrated technologies for evaluating real-world outcomes. For more information, visit outcome.com.
Paul Keckley. Executive Director, Deloitte Center for Health Solutions, the health services research arm of Deloitte LLP. For more information, visit deloitte.com.
Ken Kramer, Ph.D. Senior VP, Medical Director, Alpha & Omega, a strategic medical communications firm and a part of The Core Nation group of companies. For more information, visit aandomedcomms.com, or e-mail email@example.com.
Daniel Todd. Senior Director, Health Policy, EMD Serono Inc., an affiliate of Merck KGaA. For more information, visit emdserono.com.